About Eupraxia Pharmaceuticals Inc.
https://www.eupraxiapharma.comEupraxia Pharmaceuticals Inc., a clinical stage biotechnology company, engages in the discovery, development, and marketing of technologies in the biotechnology sector.
CEO
James A. Helliwell
Compensation Summary
(Year )
Ratings Snapshot
Rating : C+
Most Recent Analyst Grades
Grade Summary
Showing Top 1 of 1
Price Target
Institutional Ownership
ALLY BRIDGE GROUP (NY) LLC
Shares:915K
Value:$7.91M
ALYESKA INVESTMENT GROUP, L.P.
Shares:250K
Value:$2.16M
INGALLS & SNYDER LLC
Shares:59.1K
Value:$510.92K
Summary
Showing Top 3 of 4
About Eupraxia Pharmaceuticals Inc.
https://www.eupraxiapharma.comEupraxia Pharmaceuticals Inc., a clinical stage biotechnology company, engages in the discovery, development, and marketing of technologies in the biotechnology sector.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $0 | $9.58M ▼ | $-8.85M ▲ | 0% | $-0.24 ▲ | $-8.72M ▲ |
| Q2-2025 | $0 | $11.26M ▲ | $-11.91M ▼ | 0% | $-0.33 ▼ | $-11.83M ▼ |
| Q1-2025 | $0 | $10.15M ▼ | $-9.63M ▲ | 0% | $-0.3 ▼ | $-9.57M ▲ |
| Q4-2024 | $0 | $10.76M ▲ | $-10.8M ▼ | 0% | $-0.21 ▼ | $-10.75M ▼ |
| Q3-2024 | $0 | $8.51M | $-8.07M | 0% | $-0.17 | $-8.08M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $123.95M ▲ | $128.5M ▲ | $5.43M ▲ | $125.27M ▲ |
| Q2-2025 | $19.77M ▼ | $23.6M ▼ | $2.62M ▲ | $22.55M ▼ |
| Q1-2025 | $27.45M ▼ | $29.23M ▼ | $2.2M ▼ | $28.6M ▼ |
| Q4-2024 | $33.1M ▲ | $34.94M ▲ | $3.1M ▲ | $33.4M ▲ |
| Q3-2024 | $8.66M | $10.36M | $2.39M | $9.52M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-6.37M ▲ | $-4.51M ▲ | $-60.38K ▲ | $73.9M ▲ | $69.19M ▲ | $-4.57M ▲ |
| Q2-2025 | $-8.75M ▼ | $-8.32M ▼ | $-166.22K ▲ | $239.78K ▼ | $-7.69M ▼ | $-8.48M ▼ |
| Q1-2025 | $-6.77M ▲ | $-6M ▼ | $-169.04K ▼ | $429.92K ▼ | $-5.65M ▼ | $-6.17M ▼ |
| Q4-2024 | $-7.53M ▼ | $-5.97M ▲ | $-43.76K ▼ | $31.73M ▲ | $24.44M ▲ | $-6.02M ▲ |
| Q3-2024 | $-5.99M | $-10.19M | $-42.27K | $-4.6M | $-14.65M | $-10.23M |
CEO
James A. Helliwell
Compensation Summary
(Year )
Ratings Snapshot
Rating : C+
Most Recent Analyst Grades
Grade Summary
Showing Top 1 of 1
Price Target
Institutional Ownership
ALLY BRIDGE GROUP (NY) LLC
Shares:915K
Value:$7.91M
ALYESKA INVESTMENT GROUP, L.P.
Shares:250K
Value:$2.16M
INGALLS & SNYDER LLC
Shares:59.1K
Value:$510.92K
Summary
Showing Top 3 of 4